Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes

Vries, Marieke de; Westerink, Jan; El-Morabit, Fatima; Kaasjager, H. A. H.; Valk, Harold W. de

doi:10.1016/j.diabres.2022.109827

Cited by 18 publications

(25 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although T1DM accounts for only 5%‐10% of cases, the presence of altered gastrointestinal functions associated with this condition is common. In particular, dyspeptic symptoms, 79 altered esophageal and gastric motility, 39,72,106,115 constipation, alternating bowel habit, abdominal pain, bloating, flatulence, 241 chronic diarrhoea 144 and nonalcoholic fatty liver 223,224 have been frequently reported in patients with T1DM. Additionally, an increased risk of gastric, 242 pancreatic, liver, esophageal and colon cancer 243,244 has been described in subjects with T1DM.…”

Section: Gastrointestinal Alterations In Type 1 Diabetesmentioning

confidence: 99%

“…The onset and progression of NAFLD, recently re-defined Metabolic-Associated Fatty Liver Disease (MAFLD) 222 is frequently associated with insulin resistance and, thus, is a common hepatic manifestation of metabolic abnormalities, including T1DM 223,224 and T2DM. [225][226][227][228] Furthermore, the incidence of NAFLD is increasing worldwide, and this upward trend parallels that observed in both T1DM and T2DM.…”

Section: Nonalcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

See 1 more Smart Citation

Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract

Portincasa

Bonfrate

Wang

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Type 2 and type 1 diabetes are common endocrine disorders with a progressively increasing incidence worldwide. These chronic, systemic diseases have multiorgan implications, and the whole gastrointestinal (GI) tract represents a frequent target in terms of symptom appearance and interdependent pathophysiological mechanisms. Metabolic alterations linked with diabetic complications, neuropathy and disrupted hormone homeostasis can lead to upper and/or lower GI symptoms in up to 75% of diabetic patients, with multifactorial involvement of the oesophagus, stomach, upper and lower intestine, and of the gallbladder. On the other hand, altered gastrointestinal motility and/or secretions are able to affect glucose and lipid homeostasis in the short and long term. Finally, diabetes has been linked with increased cancer risk at different levels of the GI tract. The presence of GI symptoms and a comprehensive assessment of GI function should be carefully considered in the management of diabetic patients to avoid further complications and to ameliorate the quality of life. Additionally, the presence of gastrointestinal dysfunction should be adequately managed to improve metabolic homeostasis, the efficacy of antidiabetic treatments and secondary prevention strategies.

show abstract

Section: Gastrointestinal Alterations In Type 1 Diabetesmentioning

confidence: 99%

Section: Nonalcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract

Portincasa

Bonfrate

Wang

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, 3 is highly prevalent in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). 4,5 As the natural history of these two types of diabetes is different, assessing the potential effect of NAFLD on the development of T1D-or T2D-related complications would help to identify patients who might benefit from risk factor modification. However, previous observational evidence is insufficient and cannot be directly interpreted as causal because of the possibility of uncontrolled confounding and reverse causality.…”

Section: Introductionmentioning

confidence: 99%

Non‐alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study

Liu

Wang

Liu

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To investigate the potential causal relationship between non‐alcoholic fatty liver disease (NAFLD) and complications in type 1 diabetes (T1D) and type 2 diabetes (T2D). Materials and Methods Two‐sample Mendelian randomization (MR) analysis was conducted to appraise after controlling for the confounding factors. Genetic instrument variables for NAFLD surrogated by chronically elevated serum alanine transferase were derived from a recent genome‐wide association study. Diabetes‐related complications, including diabetic ketoacidosis, nephropathy and retinopathy, were included as outcomes. Four complementary MR methods were used to test reliability. Results Genetically instrumented NAFLD showed a suggestive causal association with ketoacidosis in T1D (odds ratio [OR]: 1.574; 95% confidence interval [CI]: 1.076, 2.302; P = .019; false discovery rate [FDR] = 0.096) and a significant causal association with early‐stage kidney disease in T1D (OR: 1.249; 95% CI: 1.089, 1.432; P = 1.457 × 10−3, FDR = 0.015). Sensitivity analysis indicated low heterogeneity, low pleiotropy and high reliability of the causal estimates. However, the MR analyses failed to show a causal association between NAFLD and T1D retinopathy, T2D ketoacidosis, nephropathy and retinopathy. Conclusions This study supports a causal effect of genetically driven chronic serum alanine aminotransferase‐associated NAFLD on early‐stage kidney disease in T1D and a suggestive causal effect on ketoacidosis in T1D. However, MR studies did not provide enough evidence to suggest that NAFLD independently increases the risk of retinopathy in T1D and of ketoacidosis, nephropathy and retinopathy in T2D.

show abstract

“…That study found a prevalence of 20% with NAFLD defined as CAP ≥274 dB/m. 27 Prevalence of NAFLD in our study based on CAP ≥270 dB/m was 22.4% ( Supplementary material ). A Brazilian study reported a prevalence of 12.6% based on US, and 16.8% based on CAP ≥248 dB/m.…”

Section: Discussionmentioning

confidence: 71%

Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes

Mertens¹,

Weyler²,

Dirinck³

et al. 2023

JHEP Reports

View full text Add to dashboard Cite

Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes

Cited by 18 publications

References 39 publications

Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract

Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract

Non‐alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study

Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes

Contact Info

Product

Resources

About